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Abstract
Among Swedish families with an inherited predisposition for breast cancer, less than one third segregate mutations
in genes known to be associated with an increased risk of breast cancer in combination with other types of tumours. 
In a search for new putative familial breast cancer syndromes we studied Swedish families undergoing genetic
counselling during 1992-2000. 
Four thousand families from counselling clinics in Sweden were eligible for study. Families with breast cancer
only were excluded, as were families with mutations in genes already known to be associated with malignant
diseases. We identified 803 families with two or more cases of breast cancer and at least one other type of
cancer. The observed proportion of different types of non-breast cancer was compared with the percentage
distribution of non-breast cancer tumours in Sweden in 1958 and 1999. 
We found tumours in the colon, ovary, endometrium, pancreas and liver, as well as leukaemia in a significantly
larger proportion of the study population than in the general population in both years. These tumours were also
seen among families where several members had one additional tumour, suggesting that malignancies at these
sites, in combination with breast tumours, could constitute genetic syndromes. Endometrial carcinoma has not
previously been described in the context of breast cancer syndromes and the excess of malignancies at this site
could not be explained by secondary tumours. Thus, we suggest that endometrial carcinoma and breast cancer
constitute a new breast cancer syndrome. Further investigation is warranted to categorize phenotypes of both
breast and endometrial tumours in this subgroup. 
Introduction
Breast cancer is by far the most frequently diagnosed
malignant tumour in females: one Swedish woman in ten
will be affected during her lifetime [1]. Most cases occur
late in life and are sporadic. A Scandinavian twin study
has revealed that hereditary factors are important in 27%
of all breast cancers [2], and 5-10% of the cases appear
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to be the result of autosomal dominant genes [3]. Familial
aggregations of breast cancer have been observed all
over the world; in general, early onset and bilateral
disease are two important features in these families [4].
Studies have revealed that autosomal dominant
inherited mutations in certain genes are associated with
an increased risk of breast cancer. Breast cancer in
association with other tumours constitutes different
syndromes in these families. A substantial risk of breast
cancer as well as ovarian cancer is seen in women
harbouring a mutation in BRCA1 or BRCA2 [5]. 
Although rare, other inherited syndromes associated
with an increased risk of breast cancer and other
tumours are known. An example is Li-Fraumeni
syndrome, characterised by breast cancer occurring at
an exceptionally young age in combination with brain
tumour, adrenocortical carcinoma and soft-tissue
sarcoma [6]. This syndrome has also been associated
with an overrepresentation of tumours in the stomach,
colon, rectum, pancreas and ovary, as well as
malignant lymphoma, all at an extremely young age
and along with the typical tumours constituting classical
Li-Fraumeni syndrome [7]. However, mutations in the
causative gene p53 are rarely seen in families where
breast cancer cases predominate [8]. Some families
with the Li-Fraumeni phenotype also bear mutations in
the CHEK2 gene [9]. Studies of families with multiple
cases of breast cancer have indicated that a certain
mutation in the CHEK2 gene, 1100delC, is associated
with an increased risk of both sporadic and familial
breast cancer [10]. In Cowden’s syndrome, females
are afflicted with malignant tumours of the breast and
the thyroid gland caused by germ line mutations in the
PTEN gene [11]. PTEN mutations in familial breast
cancer outside this syndrome are rare [12]. Germ line
mutations in the tumour suppressor gene E-cadherin
are associated with an increased risk of diffuse gastric
cancer and to some extent also of lobular breast
carcinoma but are not seen in familial breast cancer
without diffuse gastric cancer [13,14]. An increased
familial risk of breast cancer and pancreatic cancer
has been described in Swedish families segregating the
CDKN2A/ p16-mutation and that show multiple cases
of malignant melanoma [15]. The role of ataxia-
-telangiectasia (AT) heterozygosity in breast cancer has
been controversial. Heterozygotes have been found to
be at increased risk, in particular at older age [16].
Occasional germ line mutations have also been
reported in familial breast cancer [17]. Some recent
studies have suggested an association with breast
cancer to be restricted to certain variants of the ATM
gene [18, 19], while in others no such risk could be
demonstrated [20, 21]. 
In the counselling situation in Sweden mutation
analysis of the BRCA1 and BRCA2 genes is usually
offered to families fulfilling any of the following criteria:
1) at least three cases of breast cancer in first degree
relatives, one of whom was under the age of 50 at the
time of diagnosis, 2) two first degree relatives with
breast cancer, one before the age of 40 years, or 
3) one case of breast cancer before 35. Additional
criteria are: 4) any combination of breast cancer and
ovarian cancer in a family regardless of age, 5) one case
of ovarian cancer before age 45. Screening methods
use an exon-by-exon based strategy of both genes.
Among Swedish families with a pedigree fulfilling these
criteria less than one third segregate mutations in any
of the two genes [22-24]. Families with a distribution of
tumours typical for Li-Fraumeni syndrome are offered
mutation analyses of p53 but only a handful of germ
line p53 mutations have been found. Thus, there is
reason to believe that other syndromes with an increased
risk of breast cancer exist among the other two thirds of
the breast cancer families. The aim of the present
hypothesis-generating study was to search for putative
breast cancer associated syndromes in families with two
or more cases of breast malignancies.
Materials and methods
Four thousand Swedish families who underwent
genetic counselling during the period January 1992
to January 2000 were eligible for recruitment. This
group comprises all families in Sweden that had ever
been subject to oncogenetic counselling in an
oncogenetic clinic up to January 2000. The families
were either self-referred or referred by their doctors to
one of eight oncogenetic clinics in Sweden. Families
known to be positive for mutations in any of the genes
associated with breast or colon cancer were excluded,
as were families with any of these two malignancies as
the only observed malignancy in the family. In some
families that fulfilled the criteria, mutation screening
was not practicable, since there was no affected
woman alive to give a blood sample.
We examined all pedigrees from the 4000 families
and identified 803 families with two or more cases of
breast cancer and at least one other type of cancer and
with no exclusion criteria. These families were defined as
“study families” (Fig. 1). Diagnoses from both maternal
and paternal branches were included and every case of
cancer in first- and second-degree relatives and in first
cousins was recorded. Kinships were always related to
the proband. Malignant tumours in relatives more distant
than first cousins were included only if the diagnosis could
be verified as below. More than one study family could
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originate from one pedigree, depending on which
pedigree branch was chosen (Fig. 2A, 2B). In this way,
one case of cancer could be included in two or,
sometimes, in three study families but no case of
malignancy was ever counted more than once as an
observed case of that particular type of tumour. 
Altogether, 803 study families originated out of 750
pedigrees. The vast majority of the diagnoses were
histologically verified as shown by medical records or
the Swedish cancer registry. A few of the cases
originated from the beginning of the 20th century,
before the cancer registry was established. These cases
were mostly verified by checking the Swedish cause of
death registry, to which doctors have been required to
report all deaths since 1911.
In addition to serving as a means of verifying
diagnoses, the Swedish cancer registry was used as 
a reference population in this study. The population-
based registry, to which reporting is required by law,
was established in 1958. All new cases of malignant
primary tumours must be reported by both physician
and pathologist. In 1958, Sweden had 7.5 million
inhabitants of whom 19 324 were reported to the
cancer registry. In 1999 the corresponding figures were
8.8 million and 45 180. In order to compare our data
with official statistics of cancer incidence in Sweden, all
different subtypes of leukaemia, all soft tissue and all
central nervous system tumours were pooled in data
from 1958 as well as from 1999. In official data from
1958 tumours of lip, mouth and tongue were presented
together as were all lymphomas and myelomas. 
All families in Sweden that had 
ever been subject to oncogenetic 
counselling as of January 2000.
Families with breast cancer only
Families with colorectal cancer only
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Fig. 1. Flowchart illustrating inclusion and exclusion of study families 
Fig. 2A-B. More than one family could originate from one pedigree, depending on which pedigree branch was chosen
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The proportion of different cancers other than breast
cancer in the study families was computed and 95%
confidence intervals (CI) were calculated. When the
observed numbers were less than 10, StatXact-4 (Cytel
Inc., Cambridge, MA, USA) was used to calculate the
exact confidence interval. If the 95% CI did not cover the
proportion from 1958 (or 1999) a significant difference
from that year could be demonstrated. The population
data were obtained from official Swedish statistics from
two separate years and comparisons were made using
statistics from the first and last years for which Swedish
cancer statistics were available. Only malignancies with
a significant difference in proportions in comparison with
the general population in both 1958 and 1999 were
considered over-represented.
To make it possible to compare the frequency of non-
-breast cancers in our study families with data from
Statistics Sweden, we corrected for the fact that 87% of
the cancers reported in 1958 and 86% in 1999 were
non-breast cancers:
Total incidence of cancer in Sweden 1958 19 324
Cases of breast cancer – 2 512
–––––––––––––
All non-breast cancers in Sweden 1958 =16 812
Number of non-breast cancers in the study families 1 706
Example: Pancreas
558 cases of pancreatic cancer  558/16 812=3.31%
in Sweden
75 observed cases of pancreatic cancer in study families
75/1 706=4.396% 95% CI [3.423 – 5.369]
The 95% CI for the proportion among study
families does not cover the proportion of pancreatic
cancer among non-breast cancers in Sweden in 1958;
consequently the difference is considered significant
for that year. 
Date of diagnosis, sex and age at diagnosis were not
recorded. As the excess of ovarian cancer in the study
families could be due to “confounding by indication”,
corresponding proportions of all non-breast/ovarian
tumours with 95% CI were also calculated. We explored
the occurrence of families with one or several types of
additional malignancies including multiple cases of each
type and together with two or more breast cancer cases.
These families are defined as “multiple-case families”.
Results
In the 803 study families we found 2203 breast
cancers, equivalent to 2.7 cases per family. Thirty-five
different non-breast cancer diagnoses were observed,
totalling 1 706 cases, corresponding to 2.12 cases
per family. 
In the study families tumours in the colon, ovary,
endometrium, pancreas and liver, as well as leukaemia,
were statistically over-represented compared to the
calculated proportion from the official statistics of the
years 1958 and 1999 (Table 1). The data and method
used for comparison are described under the methods
section. Proportions of all non-breast/ovarian tumours
were also calculated using the same method with the
same five malignancies (ovarian tumours not included),
as well as malignant connective tissue tumours and
larynx, also having an observed proportion that was
significantly higher than that in the general population
in 1958 and 1999. All of the over-represented types
of cancer, except for tumours in the larynx, were also
present among the multiple case families (Fig. 3). All
cancers of the urinary tract, except for tumours of the
kidney, and all malignancies of the lymphoproliferative
system, such as lymphomas and myelomas together,
were present in a smaller proportion of the study
families than in the reference population of the Swedish
cancer registry in 1958 and 1999. 
Discussion 
Tumours in the ovary, endometrium, colon, pancreas
and liver as well as leukaemia were all found in a larger
proportion of the study population than in the reference
population in 1958 and 1999 and were also seen
among the multiple-case families. This suggests that
malignancies at these sites, in combination with breast
tumours, could constitute breast cancer syndromes.
However, there are several issues that need to be
discussed. When recording the cancer history of the study
families, we found that the vast majority of the diagnoses
recorded by the counsellor could be verified through
medical records. In our analysis we accepted both verified
diagnoses (the vast majority) and unverified diagnoses,
since in the counselling situation attempts were made to
verify diagnoses crucial for delineating the hereditary
pattern. Thus, for some malignancies, like lung cancer
and head and neck tumours, diagnoses were not always
verified. In contrast, counsellors generally made great
efforts to verify gynaecological cancers in families with 
a putative breast/ovarian syndrome, where genetic testing
is possible. By allowing also unverified diagnoses we
obtained a more complete picture of the distribution of
non-breast cancers in the families.
As many of the recorded diagnoses are dated several
years back, and the incidence of some malignant
disorders has changed over the past decades, it might
be misleading to compare the distribution of non-breast
cancers in the study families with the distribution of cancer
in general in Sweden in the late 1990s. To overcome this
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Table 1. Observed numbers and proportions of non-breast cancer in the study families compared with statistics from 1958* and 1999*
Cancer site Observed Proportion LL** 95% UL** 95% Proportion [%] Proportion [%]
Number [%] in Sweden 1958 in Sweden 1999
Colon 204 11.958 10.418 13.498 8.70 8.89
Ovary/Fallopian tube 198 11.606 10.086 13.126 4.50 2.15
Endometrium 124 7.268 6.036 8.500 4.60 3.47
Pancreas 75 4.396 3.423 5.369 3.30 2.16
Liver 39 2.286 1.577 2.995 1.37 0.83
Leukaemia 77 4.513 3.528 5.499 3.50 2.67
Prostate 157 9.203 7.831 10.575 8.88 18.94
Stomach 104 6.096 4.961 7.231 14.48 2.85
Lung 90 5.275 4.215 6.336 5.60 7.63
Uterine cervix 76 4.455 3.476 5.434 5.30 1.16
Melanoma 66 3.869 2.954 4.784 1.10 4.12
Nervous system 66 3.869 2.954 4.784 3.66 3.50
Kidney 60 3.517 2.643 4.391 3.53 2.73
Rectum 58 3.400 2.540 4.260 5.81 4.87
All lymphomas/myelomas 51 2.989 2.181 3.798 4.02 5.67
Skin 42 2.462 1.727 3.197 2.99 7.11
Urinary tract 29 1.700 1.086 2.313 3.42 5.73
All non-Hodgkin’s lymphoma 29 1.700 1.086 2.313 – 4.25
Thyroid gland 23 1.348 0.801 1.895 1.03 0.67
Conn. tissue 21 1.231 0.708 1.754 0.70 0.77
Oesophagus 20 1.172 0.662 1.683 1.10 1.04
Larynx 18 1.055 0.570 1.540 0.60 0.47
Mouth/Lip/Tongue 17 0.996 0.525 1.468 1.67 1.27
Myelomas 17 0.996 0.525 1.468 – 1.43
Biliary tract 15 0.879 0.436 1.322 1.26 1.11
Mouth 11 0.645 0.265 1.025 – 0.50
Small intestine 10 0.586 0.224 0.948 0.33 0.52
Bone 8 0.469 0.200 0.920 0.53 0.15
Testis 7 0.410 0.170 0.840 0.50 0.66
Vulva/Vagina 7 0.410 0.170 0.840 0.73 0.52
Hodgkin’s lymphoma 5 0.293 0.100 0.680 – 0.45
Salivary gland 5 0.293 0.100 0.680 0.31 0.25
Adrenal gland 4 0.234 0.060 0.600 – –
Pharynx 4 0.234 0.060 0.600 0.71 0.58
Lip 4 0.234 0.060 0.600 – 0.42
Nose/Sinuses 3 0.176 0.040 0.510 0.49 0.15
Tongue 2 0.117 0.010 0.420 – 0.36
*Cancer incidence in Sweden 1958 and 1999: Swedish National Board of Health and Welfare 1958 and 1999 respectively.
**Lower Limit [LL] Upper Limit [UL].
If the 95% CI covers the proportion from 1958 (or 1999), no significant difference from that year can be demonstrated 
When the observed frequency is less than 10 an exact confidence interval for the proportion is calculated. 
Diagnoses in bold indicate a type of tumour in study families with a proportion with 95% CI that does not cover the proportion demonstrated in the Swedish
Cancer registry in both 1958 and 1999.
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problem we used official statistics from two separate years
for comparison. The first and the last years for which
official Swedish cancer statistics are available – 1958
and 1999 – were chosen to capture as many as possible
of the changes in cancer incidence over the years. 
The official statistics used for comparison in our study did
not take gender or age at diagnosis into account; nor
do our data. 
The use of expanded pedigrees of individuals from
all branches can be questioned. It can result in an
overestimation of the cancer incidence when more than
one study family is registered from one pedigree. 
To overcome this problem, all counted families were
studied but individual tumours were only included once
as an observed case of that particular type of tumour.
Thus, even though this might exaggerate the total
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number of non-breast cancer cases in the study
families, it should not influence the distribution of the
different kinds of tumours. 
Since the statistics from 1958 report tumours of the
lip, mouth and tongue all together, and the same for
lymphomas and myelomas, the distribution of these
disorders could not be compared individually with
figures describing their distribution in the study families. 
A substantial number of probands at the oncogenetic
clinics in Sweden ask for genetic counselling because of
several cases of colon cancer in close relatives. As breast
cancer is a fairly common malignant disease, two or more
cases could occur simply by chance in these families. This
might explain a minor fraction of the observed excess of
colon malignancies in the study families. The observed
excess of ovarian cancer cases could be explained by
undetected BRCA1 and BRCA2 mutations. However, the
screening techniques in use today detect small single
base-pair alterations, insertions and deletions as well as
large rearrangements, making it unlikely that many of
our breast-ovarian cancer families segregate undetected
BRCA1/2 mutations. Even if the sensitivity of the molecular
techniques is not 100 percent it cannot be excluded that
a still unknown gene, associated with breast / ovarian
cancer syndrome, could account for some of the
observed cases. The excess of endometrial carcinoma
could correspond to the previously described combination
of papillary serous adenocarcinoma of endometrium and
breast cancer [25] but probably only accounts for a minor
part of the observed cases. In hereditary non-polyposis
colorectal cancer (HNPCC), tumours in the colon are
frequently seen in combination with other malignancies,
e.g. endometrial cancer. However, among cases of
endometrial cancer in our study families, only four out of
124 cases occurred in combination with colon cancer,
thus suggesting that the observed excess of endometrial
malignancy would not be a result of HNPCC in our
families. Further investigation is warranted to categorize
phenotypes of both breast and endometrial tumours in
this subgroup. The excess of pancreatic tumours could
in part be due to CDKN2A/ p16-mutation-positive
Swedish families. As discussed above, some of the
diagnoses were never verified but simply recorded as the
type of malignancy known to the proband. Secondary
tumours or metastases from different cancer sites are
commonly seen in lung, liver and bone and could
probably explain some of the tumours observed at these
sites. Nevertheless, only malignancy in the liver was seen
more often in the study families than in the reference
population, indicating that diagnoses at these three sites
are probably not exaggerated. Leukaemia is seen in 
Li-Fraumeni syndrome and study families with mutations
in TP53, CHEK2 or other genes in the same pathway
could explain the excess of this type of malignancy.
The findings of the present study are in congruence
with the findings of Bermejo and Hemminki [26]
showing an association between breast cancer and
ovarian, colon, endometrial and pancreatic cancer in
study populations from Sweden. 
We suggest that breast cancer in combination with
tumours in the colon, ovary, endometrium or pancreas,
or leukaemia, could constitute genetic breast cancer
syndromes. Earlier described syndromes could, at least
in part, explain the higher frequency of tumours in ovary
and pancreas and leukaemia in study families. The
excess of cancer in ovary and colon could partly be 
a result of confounding by indication. Neither can we
rule out the possibility that the excess of malignancies
in the liver is a result of secondary tumours in the study
families. However, endometrial carcinoma has not been
described previously in that context, suggesting that
endometrial carcinoma and breast cancer could
constitute a new breast cancer syndrome. The result
can be used to define subgroups of families suitable
for studies aiming to identify additional genes
predisposing to breast and endometrial cancer.
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